# NAD+ Injection: Subcutaneous and Intramuscular Protocols in the Research Literature

> NAD+ injection — subcutaneous and intramuscular protocols, reconstitution, dose ranges studied, and how injectable NAD+ compares to IV infusion and oral precursors.

## What Is an NAD+ Injection?

An NAD+ injection is a subcutaneous (SC) or intramuscular (IM) administration of compounded NAD+ solution, delivering the molecule directly into tissue and bypassing the gastrointestinal degradation that limits oral NAD+ bioavailability. In the pharmacology hierarchy, injectable NAD+ sits between oral precursors (lowest plasma NAD+ elevation) and intravenous infusion (highest plasma elevation).

As of 2026, SC and IM NAD+ injection protocols are active in registered clinical trials (including NCT06919328 and NCT07251608) but no completed, peer-reviewed RCT for these specific routes has been published.

## Are NAD+ Injections Supported by Research?

The direct evidence base for SC/IM NAD+ injection is limited. What the adjacent literature establishes:

**Oral NMN and NR RCTs** confirm that raising the NAD+ pool produces measurable physiological effects — blood NAD+ elevation, muscle insulin sensitivity improvement, physical function gains — at dose ranges of 250–900 mg/day [4, 5, 6, 7].

**IV NAD+ case series and pilots** show that injectable administration achieves plasma NAD+ elevations far exceeding oral dosing and produces functional outcomes in addiction and neurochemical settings [9, 11, 12].

## NAD+ Dosage in Research Protocols

The following reflects the documented research record — not a dosing recommendation.

**Oral NMN:**
- Single-dose safety: 100, 250, 500 mg (Irie et al. 2020) [3]
- 250 mg/day × 12 weeks: blood NAD+ elevated at weeks 4, 8, 12 (Okabe et al. 2022) [4]
- 250 mg/day × 10 weeks: muscle insulin sensitivity improved (Yoshino et al. 2021) [5]
- 300–900 mg/day × 60 days: 600 mg/day optimal (Yi et al. 2022) [6]
- 250 mg/day × 12 weeks: gait speed and grip strength improved in older men (Igarashi et al. 2022) [7]
- 300–1200 mg/day × 6 weeks with exercise: VO₂max improved at 600 and 1200 mg/day (Liao et al. 2021) [17]

**Oral NR:**
- 100–1000 mg/day × 8 weeks: blood NAD+ +22%, +51%, +142% (Conze et al. 2019) [8]
- 3000 mg/day × 30 days in Parkinson disease: safe; no serious AEs (Berven et al. 2023) [18]

**Intravenous NAD+:**
- 750 mg over 6 hours (~2 mg/min rate): plasma NAD+ elevated; PK profile established (Grant et al. 2019) [9]
- 500–1000 mg/day IV × 4 days: historical addiction protocols (O'Hollaren 1961, reviewed 2020) [12]

**SC/IM injection:**
- Practitioner protocols: 100–500 mg, 1–3 times weekly
- No completed published RCT as of 2026; active registered trials

## NMN Dosage Studied in Adults Over 50

- 250 mg/day × 10 weeks in postmenopausal women with prediabetes: skeletal muscle insulin sensitivity improved (Yoshino et al. 2021) [5]
- 250 mg/day × 12 weeks in healthy older men: gait speed (p=0.033) and grip strength (p=0.019) improved (Igarashi et al. 2022) [7]
- 600 mg/day identified as optimal in multicenter RCT of middle-aged adults (Yi et al. 2022) [6]

---

Chrome-console readings of the peer-reviewed NAD+ record — clinical trials indexed, infusion rates logged, no prescriptions filled.